Drug recall · October 23, 2019
Pioglitazone Hydrochloride Tablets USP 15 mg recall
Why: Superpotent
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Pioglitazone Hydrochloride Tablets USP 15 mg, 30 count bottles, Rx only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India NDC 33342-054-07
- Lots / codes
Lot # BPF901A, exp. date 12/2021
- Quantity
- 31,968 bottles
- Company
- Macleods Pharma Usa Inc, Plainsboro, NJ
- Distribution
- Product was shipped to 8 distributors who may have further distributed the product.
- Initiated
- September 23, 2019 · Voluntary: Firm initiated
- Classified
- October 11, 2019
- Reported
- October 23, 2019
- Ended
- February 23, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Pioglitazone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.